National Bank of Canada FI Has $4.40 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

National Bank of Canada FI lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 12.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,855 shares of the medical research company's stock after acquiring an additional 2,639 shares during the period. National Bank of Canada FI's holdings in Charles River Laboratories International were worth $4,396,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Public Sector Pension Investment Board increased its holdings in shares of Charles River Laboratories International by 15.1% during the 3rd quarter. Public Sector Pension Investment Board now owns 2,282 shares of the medical research company's stock worth $449,000 after purchasing an additional 300 shares during the period. Benjamin Edwards Inc. increased its stake in Charles River Laboratories International by 256.5% during the third quarter. Benjamin Edwards Inc. now owns 1,451 shares of the medical research company's stock valued at $286,000 after acquiring an additional 1,044 shares during the period. Janus Henderson Group PLC raised its holdings in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after acquiring an additional 3,268 shares in the last quarter. Quantinno Capital Management LP lifted its position in shares of Charles River Laboratories International by 27.9% in the 3rd quarter. Quantinno Capital Management LP now owns 20,706 shares of the medical research company's stock worth $4,078,000 after acquiring an additional 4,516 shares during the period. Finally, State Street Corp grew its holdings in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Remove Ads

Insider Activity

In other news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO James C. Foster acquired 6,075 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded down $0.39 during trading on Friday, reaching $99.56. The company's stock had a trading volume of 11,602,556 shares, compared to its average volume of 856,742. The stock has a 50-day moving average price of $156.71 and a two-hundred day moving average price of $177.01. The stock has a market capitalization of $4.89 billion, a P/E ratio of 663.71, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.46 earnings per share. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analysts Set New Price Targets

CRL has been the subject of a number of recent research reports. Morgan Stanley cut their target price on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. Barclays dropped their price objective on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a research note on Thursday. Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. Mizuho dropped their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday. Finally, William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and an average price target of $182.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).